Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Armuzzi

Showing results (311-320 of 320) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 320 results.
Inflammatory Bowel Diseases|May 17, 2022
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational StudyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in ItalyAntonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
United European Gastroenterology Journal|January 18, 2025
Inter-Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five-Nations Survey StudyOffir Ukashi, Aurelien Amiot, David Laharie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitisGiuseppe Privitera, Cristina Bezzio, Gisella Figlioli, et al.
Journal of Crohn'S & Colitis|November 3, 2025
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment classTommaso Innocenti, Jurij Hanžel, Marie Truyens, et al.
Inflammatory Bowel Diseases|February 11, 2025
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus ConferenceLoris R Lopetuso, Sara Deleu, Pierluigi Puca, et al.
Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Journal of Crohn'S & Colitis|July 27, 2022
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European StudyHenit Yanai, Anna Kagramanova, Oleg Knyazev, et al.
Pageof 32

Showing results (311-320 of 320) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 320 results.
Inflammatory Bowel Diseases|May 17, 2022
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational StudyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|December 19, 2022
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in ItalyAntonio Tursi, Giammarco Mocci, Antonio Cuomo, et al.
United European Gastroenterology Journal|January 18, 2025
Inter-Rater Disagreements in Applying the Montreal Classification for Crohn's Disease: The Five-Nations Survey StudyOffir Ukashi, Aurelien Amiot, David Laharie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 30, 2026
Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitisGiuseppe Privitera, Cristina Bezzio, Gisella Figlioli, et al.
Journal of Crohn'S & Colitis|November 3, 2025
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment classTommaso Innocenti, Jurij Hanžel, Marie Truyens, et al.
Inflammatory Bowel Diseases|February 11, 2025
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus ConferenceLoris R Lopetuso, Sara Deleu, Pierluigi Puca, et al.
Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
The American Journal of Gastroenterology|February 18, 2026
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD StudyFranco Scaldaferri, Federica Di Vincenzo, Marina Aloi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.
Journal of Crohn'S & Colitis|July 27, 2022
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European StudyHenit Yanai, Anna Kagramanova, Oleg Knyazev, et al.
Pageof 32